Skip to content
Human-limitedGLP-1 analog for daily weight management

Liraglutide

Short-acting GLP-1 agonist for weight loss & diabetes.

Overview

Activates GLP-1 receptors in pancreas (glucose-dependent insulin), gut (gastric emptying), and hypothalamus (satiety).

Proposed mechanism

Liraglutide is a GLP-1 receptor agonist with 97% homology to human GLP-1, stimulating insulin secretion, delaying gastric emptying, and reducing appetite.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Liraglutide for obesity (SCALE)

    · DOI:10.1056/NEJMoa1411892 · 2015

  2. [2]

    LEADER trial cardiovascular

    · DOI:10.1056/NEJMoa1603827 · 2016

  3. [3]

    Liraglutide for obesity (SCALE) (2015)

    · · 0

  4. [4]

    LEADER trial cardiovascular (2016)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

AICAR

Human-limited

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

0 RCT · 0 human · 0 preclinical

metabolic

AOD-9604

Anecdotal

HGH fragment for lipolysis stimulation

HGH fragment for localized fat metabolism.

0 RCT · 0 human · 0 preclinical

fat-loss